CLDX -
Celldex Therapeutics, Inc
| Day |
1m |
10m |
60m |
PreMarket |
Market |
AfterHours |
Gap |
| 25.49 0.48 (1.88%) |
-0.02 (-0.06%) |
-0.04 (-0.15%) |
-0.01 (-0.04%) |
-0.39 (-1.53%) |
1.04 (4.17%) |
--- |
-0.39 (-1.53%) |
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
Earnings & Ratios
- Basic EPS:
- -0.85
- Diluted EPS:
- -0.85
- Basic P/E:
- -30.5529
- Diluted P/E:
- -30.5529
- RSI(14) 1m:
- 64.29
- VWAP:
- 25.98
- RVol:
Events
| Period |
Kind |
Movement |
Occurred At |
Related News
Chronic Inducible Urticaria (CIndU) Market Research Report 2025-2035 | Competitive Analysis of AstraZeneca, Celldex Therapeutics, J&J, Merck, Novartis, Pfizer, Regeneron Pharma, Sanofi, Sun Pharma
Aug 27, 2025 08:50
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025
Jun 14, 2025 14:48
Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025
Mar 03, 2025 13:01
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
Mar 01, 2025 17:45
Chronic Spontaneous Urticaria Market to Register Incremental Growth During the Study Period (2020–2034) Owing to the Launch of Emerging Therapies | DelveInsight
Feb 20, 2025 18:00
Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis
Dec 19, 2024 13:01
Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight
Nov 04, 2024 18:00
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
Oct 26, 2024 21:43
Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024
Oct 25, 2024 12:01
Analyst Expectations For Celldex Therapeutics's Future - Benzinga
Jul 16, 2024 19:01